Actin-based protrusions driving cell migration are reinforced through positive feedback, but it is unclear how the cell restricts the eventual size of a protrusion or limits positive signals to cause splitting or retraction. We have identified an evolutionarily conserved regulator of the protrusion machinery, which we name CYRI (CYFIP-related Rac interacting) protein. CYRI shows sequence similarity to the Scar/WAVE complex member CYFIP in a Domain of Unknown Function, DUF1394. CYRI binds specifically to activated Rac1 via a common motif shared with CYFIP, establishing DUF1394 as a new Rac1 binding domain. CYRI-depleted cells have broad, Scar/WAVE-enriched lamellipodia and enhanced Rac1 signaling. Conversely, CYRI overexpression suppresses spreading and dramatically sharpens protrusions into unproductive needles. CYRI proteins use dynamic inhibition of Scar/WAVE induced actin to focus positive protrusion signals and regulate pseudopod complexity. CYRI behaves like a "local inhibitor" predicted and described in widely accepted mathematical models, but not previously identified in living cells.
Introduction
Cell migration is an ancient and fundamental mechanism by which cells interact with their environment -from seeking nutrients to organizing into specialized tissues. Motile cells have the intrinsic ability to polymerise actin and make protrusions that drive migration. Dozens of proteins regulate the polymerization of actin both spatially and temporally, enabling the cytoskeleton to perform complex and specialised behaviours. The relationship between de novo pseudopod generation, pseudopod splitting and retraction during cell translocation is an area of active debate 1 . The 5-protein Scar/WAVE complex is the main driver of Arp2/3 complex induced branched actin networks underlying pseudopod generation. Scar/WAVE is normally autoinhibited until signals from the activated small GTPase Rac1 interacting with the CYFIP subunit (PIR121 in Dictyostelium) cause a conformational change leading to interaction with and activation of Arp2/3 complex 2, 3 . How this activation mechanism is modulated or attenuated is not known, but it is clear that the Scar/WAVE complex is part of a multicomponent network of regulation of which we only currently understand a small fraction of the players. Rac1 is one of the activators of Scar/WAVE, but studies in live cells have revealed much faster dynamics of Scar/WAVE recruitment and turnover at the leading edge than Rac [4] [5] [6] . At least three negative regulators of Arp2/3 complex have been described, Gadkin 7 which sequesters Arp2/3, PICK1 (whose role as an Arp2/3 inhibitor is still under debate) 8, 9 and Arpin, which mimics the tail of WASP proteins but inhibits rather than stimulating the Arp2/3 complex 10 . Here, we describe the first negative regulator of Scar/WAVE complex activation by Rac1, CYRI (encoded by the FAM49 gene), an evolutionarily conserved protein that mimics the Rac1 interaction domain of CYFIP/PIR121 and thus acts as a direct local competitor for activated Rac1 at the plasma membrane.
Results

CYRI is an evolutionarily conserved N-myristoylated protein with homology to CYFIPs
We sought new interactors of the Scar/WAVE complex by pulldown of GFP-Nap1 (NCKAP1 in mammals) of the Scar/WAVE complex 11 stably expressed in Nap1 knockout Dictyostelium cells. Reversible formaldehyde crosslinking in cellulo 12 stabilised transient interactions and subsequent GFP-trap immunocapture recovered Scar/WAVE complex members Scar/WAVE, ABI, HSPC300 and PIR121 (CYFIP1/2 in mammals). Among other interactors, we noticed an associated uncharacterized protein with homology to human FAM49 (for family of unknown function 49) ( Fig 1A and Table S1 ). Even though subsequent attempts to immunoprecipitate FAM49 with the Scar/WAVE complex in the absence of crosslinking showed that this interaction likely indirect, FAM49 caught our attention for two reasons. Firstly, it is highly conserved across evolution, hinting at a fundamental function (Supplementary Fig.1A) . FAM49 is present in all of the major eukaryotic superfamilies (as defined by Keeling et al. 13 )-unikonts, chromalveolates, excavates and at least one example in plants and is roughly coconserved with the Scar/WAVE complex ( Supplementary Fig.1B) . Secondly, both Pfam and InterPro identified FAM49 as sharing a DUF1394 domain with CYFIPs (Fig. 1B-D and Supplementary Fig.1C ) suggesting a functional linkeage constitutively active RhoA Q63L or Cdc42 Q61L (Fig. 2D-E and Supplementary Fig.  2B ). We tested the Rac1 CYRI-RBD interaction directly using purified recombinant proteins and surface plasmon resonance. Immobilised Rac1 Q61L specifically bound to purified CYRI-B RBD with a Kd of 27 µM and the reverse assay, with CYRI-B RBD immobilised returned a similar Kd of 22 µM (Fig. 2F) . Thus, we conclude that CYRI-B RBD directly interacts with purified active Rac1 and shows specificity for Rac1 over Cdc42 and RhoA. The relatively low affinity of CYRI-B for Rac1 compared with PAK-CRIB (Kd = 0.05 µM 20 ) is consistent with the low affinity of Rac1 for Scar/WAVE complex (1-10 µM 2 ) and the need for a dynamic interaction at the cell leading edge. Furthermore, Scar/WAVE complexes act in clusters at the plasma membrane 21, 22 , where CYRI likely modulates coincidence detection of activation signals 21, 22 . We thus conclude that CYRI-B selectively binds to activated Rac1, similarly to CYFIP1 2 , thus defining the DUF1394 as a new dynamic detector of activated Rac1 and potential modulator of the coincidence detection by Scar/WAVE complex.
To test our hypothesis that CYRI-B would modulate the Rac1 and Scar/WAVE dynamic interaction in cells, we used a dark acceptor Raichu FRET probe 23, 24 to measure activity of Rac1 in cells where we perturbed CYRI-B. Fig. 2G-H ). This drop in Rac1 activation signal upon CYRI-B expression was fully reversed by mutation of Arg160 and Arg161 to aspartic acid (R160/161D mutant, Fig. 2K ). Thus, as well as interacting with Rac1 directly, CYRI-B buffers Rac1 activity at the plasma membrane. This suggests that CYRI-B is a negative regulator of Rac1 and Scar/WAVE induced actin assembly in cells, by binding to Rac1 and lowering its activity, in competition for the interaction between CYFIP and active Rac1.
To determine whether Rac1 was required for the exaggerated lamellipodial phenotype of CYRI-B knockout cells, we co-depleted Rac1 and CYRI-B from fibroblasts cultured from a conditional inducible Rac1 knockout mouse 26 . We used ROSA26-Cre::ER T2+ ;p16Ink4a -/-, Rac1 fl/fl mouse tail fibroblasts, treated or not with hydroxytamoxifen (to induce deletion of Rac1) and then with siRNA against CYRI-B. Deletion of Rac1 led to a spindle-shaped morphology and a loss of lamellipodia as previously described [27] [28] [29] . Loss of CYRI-B did not cause excessive lamellipodia or altered circularity in Rac-deleted cells ( Supplementary Fig. 3G-J) . Thus, Rac1 is absolutely required for CYRI-B driven actin reorganisation. Overall, therefore, CYRI-B knockout cells show excessive Scar/WAVE driven lamellipodia, caused by Rac1 activation, leading to an increase in spread area. This supports a role for CYRI-B as a buffer of Rac1 activity at the leading edges of cells, regulating activation of the Scar/WAVE complex.
If CYRI is a negative regulator of Rac1 and Scar/WAVE, then increasing expression should oppose lamellipodia. Most cell lines did not tolerate CYRI-B overrexpression, but a doxycycline inducible system in COS-7 cells with a coexpressed membrane-targeted mVenus provided up to 5-fold CYRI-B enrichment after 48h of induction ( Supplementary Fig. 2G ). Overexpressors frequently appeared smaller, lacked lamellipodia and were either not spread at all or (around 50%) showed highly complex fractal pseudopods with loss of lamellipodia, and consequently decreased circularity. WAVE2 staining at the cell edge was also greatly diminished (Fig. 3H-K and Supplementary Fig. 3K-N) . We therefore conclude that overexpression of CYRI-B opposes lamellipodia assembly, maintenance and spreading, all of which require constant polymerization of actin to support retrograde flow. The phenotype is however, different from loss of Rac1 (e.g. see Supplementary Fig. 3H ), which makes cells become spindle-shaped [27] [28] [29] . This suggests that CYRI-B has a more specific role than Rac1, involving negative regulation of the Rac1 -Scar/WAVE complex pathway at the plasma membrane.
We next localised CYRI-B within cells. No commercially available antibodies gave a reliable signal (not shown), and GFP-CYRI-B or CYRI-B-GFP was not tolerated by cells, nor showed any specific localization. However, low levels of CYRI-B tagged with FLAG, which is much smaller than GFP (Supplementary Figure 3O) revealed a striking peripheral localization of CYRI-B similar to WAVE2, and a gradient of CYRI-B localization across the cell (Fig. 3L-M) . CYRI-B levels were at their peak in areas where lamellipodia protrusions were visible by actin staining. This localization suggests that CYRI-B is recruited by the same signals as the Scar/WAVE complex to areas of active protrusion.
CYRI focuses actin assembly in leading pseudopods to promote plasticity of migration As lamellipodia and Rac1 -Scar/WAVE are major regulators of cell migration, we explored a role for CYRI-B in 2D migration and 3D invasion. CHL1 human melanoma cells were sparsely seeded onto fibronectin-coated dishes and viewed for 17h by timelapse microscopy. CYRI-B knockout cells migrated on average 1.5 fold faster and travelled a greater aggregate distance (Fig. 4A-B) . Furthermore, 7 CYRI-B knockouts were more invasive and migrated further in two different Matrigel invasion assays ( Supplementary Fig. 4A-D) . Thus CYRI-B controls migration and may restrict cancer invasion, via its regulation of Rac1 and Scar/WAVE complex 30 .
To analyse the mechanisms of CYRI-B migration suppression, we studied the shapes of the faster moving cells in 2D random migration assays. Time-lapse microscopy revealed that CYRI-B knockout cells frequently adopted a C-shape when migrating across a flat 2D surface, with a broad spread lamellipodium spanning approximately the front half of the cell perimeter and a convex rear (Fig. 4C yellow arrows, Supplementary video 1) . This was also quantified by immunofluorescence of CYRI-B knockout cells (Fig. 4D-E) . These C-shaped cells resembled the fast-moving goldfish keratocyte 31 and moved faster than cells displaying other shapes in videos. Migration speed correlated positively with the time spent as a C-shape (Fig. 4F) . CYRI-B knockout cells showed a higher percentage of C-shaped cells when migrating, and spent a larger proportion of their time as a C-shape than wild type cells (Fig. 4G,H) . Finally, the C-shaped cells migrated faster than randomly shaped cells in both wild type and CYRI-B knockouts, and CYRI-B knockouts of both C-and random shapes travelled faster than wild type counterparts (Fig. 4I) . Our results suggest that CYRI-B knockout cells have a uniformly high state of active Rac1 and Scar/WAVE complex at their periphery, and consequently less ability to form complex multi-protrusion shapes. Cells with a uniform lamellipod all around the perimeter do not move efficiently, but if they break symmetry and assume a C-shape, the lamellipod in front is stable and cells migrate rapidly. The importance of symmetry breaking for migration has previously been described for cell fragments 32 and in experiments where symmetry was broken by adding inhibitors locally with a micropipette 33 . There is an optimal level of Rac1 activity for efficient migration 29, 34 and in adherent cells, we propose that loss of CYRI enhances Rac1 activity and thus migration speed at the expense of complexity and plasticity of pseudopod extensions.
CYRI promotes pseudopod splitting in Dictyostelium
To test conservation of CYRI function, Dictyostelium cells (AX3, CYRI knockout and rescue) were migrated under agarose towards folate (Fig. 5A,  Supplementary Movie 3) . CYRI knockout cells were rounder and displayed blunted protrusions (Fig. 5A-B, Supplementary Movie 3) and a decreased protrusion frequency (from ~5/min to ~2/min, Fig. 5C ) and a decreased rate of pseudopod splitting (Fig. 5D) . We also rescued CYRI knockouts with CYRI or CYRI R155/156D (mutated analogously to mammalian CYRI-B R160/161 ) as stable, single-copy REMI transfectants 35 under an actin15 promoter (Fig. 5 A-D,  Supplementary Movie 3) . CYRI WT expressing cells showed increased complexity at their leading edges over wild-type cells, exhibiting more numerous fractal and branched pseudopods (Fig. 5A) . As expected, CYRI WT restored the circularity and enhanced the frequency of protrusion generation (around 7/min, Fig. 5C ) and an enhanced rate of pseudopod splitting (around 3.5/min, Fig. 5D ) even over WT cells. The enhanced rates and slightly fractal appearance of rescued cells were presumably due to mild overexpression; similar results were obtained with independent knockouts and extrachromosomal re-expression 8 ( Supplementary Fig. 5A-C) . The migration speed of CYRI null cells was modestly reduced (from around 0.25um/sec to 0.15um/sec) and was rescued with re-expression of CYRI WT but not mutant CYRI R155/156D (Supplementary Fig.  5D ), confirming the importance of CYRI' interaction with Rac. The chemotactic index of cells migrating toward a folate gradient was barely affected by knockout or re-expression, remaining around 0.5-0.6 (Supplementary Fig. 5E ). Pseudopod protrusion correlates with persistent migration, so we examined the directness of migration, by comparing the distance between two points and the total path length taken by cells migrating between them. Loss of CYRI caused a small increase in the directness (Fig. 5E) , reflecting the increased tendency to create single broad stable pseudopods as they migrated. As expected, CYRI WT rescue decreased the directness of migration in line with the fractal nature of the cells, and the mutant CYRI R155/156D was not significantly different from the knockout, giving no rescue (Fig. 5E ).
As in mammalian cells, altering CYRI affected recruitment of Scar/WAVE complex to the edges of migrating cells, leading to broad pseudopods and altered motility. The Scar/WAVE complex is recruited to the pseudopods of both WT and CYRI knockout cells with a very different profile ( Fig. 5F and Supplementary Movie 4). Scar/WAVE complex (indicated by HSPC300-GFP 5 ) forms a thick and restricted patch at the ends of extended pseudopods whereas the signal is more noisy, diffuse and broad in the knockout cells. This phenotype is similar to mammalian CYRI-B knockout cells, where extensive Scar/WAVE2 recruitment was apparent around the cell periphery in broad regions. Thus, CYRI has a conserved function to restrict the accumulation of the Scar/WAVE complex at the cell edge and to sharpen and enhance individual pseudopods to provide control of cell migration.
CYRI is a locally acting negative inhibitor of actin assembly signals
It is widely accepted that actin assembly pathways are not linear cascades, but rather feedback loops where positive stimulation is self-reinforcing and causes further activation until overcome by negative feedback 36, 37 . In models of migration based around positive feedback, for example the mathematical model of Meinhardt 38 , inhibitors are required to limit the amount of cell edge devoted to pseudopods. A locally-acting inhibitor is also needed to destabilise existing pseudopods, so the cell can change direction. Thus the effect of the local inhibitor is to make pseudopods more dynamic, with old pseudopods being removed, and new ones being created. We used a published simulation 39 based on the Meinhardt model 38 to visualise the concentrations of the activator and the local inhibitor at the cell edge ( Supplementary Fig. 6 and Supplementary Movie 5), to provide a clear illustration of the proposed role for CYRI-B in regulation of Rac1 and Scar/WAVE signaling. A peak in the activator (which represents, for example, active Rac and Scar/WAVE) results in the formation of a new pseudopod. The peak also causes an increase in the concentration of the local inhibitor, which is smaller and thus diffuses faster. This causes two changes -initially, it limits the lateral spread of the pseudopod ( Supplementary  Fig. 6, panel 1) ; later, levels of inhibitor rise in the middle of the pseudopod, destabilizing it and causing it to split (Supplementary Fig. 6, panel 2) . The weaker of the pseudopods then retracts and the stronger is reinforced until the cycle of inhibition catches up with it and starts the splitting all over again ( Supplementary Fig. 6 , panels 3-4). The local inhibitor thus increases both the morphological complexity of the cell and the competition between pseudopods. CYRI resembles Meinhardt's local inhibitor in several ways. Its loss causes pseudopods to spread; overexpression makes pseudopods in both mammalian and Dictyostelium cells narrower. Similarly, pseudopods in the cells lacking CYRI are far less dynamic, while they change rapidly in overexpressers. Thus, Meinhardt's model offers insight into the role of CYRI proteins as local inhibitors which perhaps counterintuitively enhance leading edge dynamics and add plasticity to the positive feedback loops driving migration.
Discussion
The broader implications of CYRI modulation of actin cytoskeletal control remain to be determined for normal and tumour cells. Modulating CYRI expression levels can either speed up or slow down cell migration depending on the circumstances. For example, we saw faster migration in 2D assays (Fig. 4) and increases in 3D invasion in CHL1 cells ( Supplementary Fig. 4 ) but Dictyostelium cells lacking CYRI migrated modestly more slowly (Supplementary Fig. 5D ). Migration speed is a complex parameter and depends on a balance between many factors including adhesion, protrusion and contractility. Dictyostelium cells already show optimal migration due to constitutive front-rear polarization and relatively low adhesion to rigid surfaces, so a change in the balance of Rac1 and Scar/WAVE activation may slow them down. Mammalian cancer cells or fibroblasts migrate orders of magnitude more slowly on similar surfaces, so increases in Rac1 signaling upon loss of CYRI-B may thus increase their speed. The gene encoding CYRI-B is located on chromosome 8q24, near Myc and is thus genetically co-amplified with the Myc oncogene in many cancers (C Bioportal database). Coupled with a potential role in invasion, which we highlight here ( Supplementary Fig. 4 ), we predict an interesting role for CYRI in cancer.
CYRI proteins represent new fundamental direct negative regulators of the Rac1 -Scar/WAVE pathway and the DUF1394 is here identified as a new module specifically binding to active Rac. Previous studies have identified negative regulation at the level of Arp2/3 complex and positive regulators of Scar/WAVE complex such as lamellipodin 40, 41 , but CYRI is the only locally acting negative regulator of Rac1-Scar/WAVE activation. CYRI competes with CYFIP to interact with active Rac1 and thus dampens the activation of Scar/WAVE complex by active Rac1. This local dampening of the signal focuses activation to the central regions of the highest active zones and thus sharpens pseudopod protrusions. CYRI thus allows the cell to generate highly flexible and dynamic protrusions that can split and facilitate changes in direction. How CYRI is regulated and the structural nature of its interaction with Rac1 are among the many interesting questions for the future. Supplementary Fig. 2A ).
B -Western blot images from pulldown of GST control, GST-Rac1 WT or GSTRac1 Q61L immobilized on beads, mixed with lysate from CHL1 cells expressing either GFP alone, eCFP-CRIB-PBD, GFP-RBD WT , GFP-RBD R160D or GFP-RBD R161D . Binding (arrow) was quantified relative to the input using densitometry (C).
D -Pulldown of GST control, or GST-tagged Rac1 WT , Rac1 Q61L , RhoA Q63L , Cdc42 Q61L immobilized on beads, mixed with lysate from CHL1 cells expressing GFP alone or GFP-RBD WT . Binding (arrow) was quantified relative to the input using densitometry (E). All data shown in this figure are representative of at least 3 independent experiments unless specified. Scale bar = 10μm Bar and scatter plots show data points with mean and SEM. N-terminal myristoylation site of CYRI 10 20
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